All research
2026-07-09 PubMed

High-resolution tandem mass spectrometry strategy directly distinguishes Leucine and Isoleucine residues in peptides

Direct Characterization of Leucine and Isoleucine Residues in Peptides Using High-Resolution Tandem Mass Spectrometry.

Background

Accurate identification and assignment of Leucine (Leu) and Isoleucine (Ile) residues, collectively termed Xle, are critically important for peptide drug safety and efficiency. Despite their identical molecular masses, these isomers can exert distinct biofunctional properties depending on their position within a peptide sequence. Traditional mass spectrometry struggles to differentiate them due to this mass identity, creating a significant analytical challenge in peptide drug research and development (R&D) and quality control (QC), where precise structural characterization is paramount.

Study Design

Researchers developed a high-resolution tandem mass spectrometric strategy combining high-energy collision dissociation (HCD) and collision-induced dissociation (CID) to differentiate Leu and Ile. The method first used HCD to generate immonium ions (m/z 86.1) from Xle residues. Subsequently, the fragmentation behavior of these immonium ions was investigated using CID in the m/z range of 40-90. This analysis was performed on an Orbitrap Eclipse Tribrid mass spectrometer and applied to various peptides, including those with different structures (linear and cyclic) and lengths (short and long), to characterize single and multiple Xle residues.

Results

The study successfully identified two diagnostic product ions, m/z 44.0 and m/z 69.0, resulting from the CID fragmentation of the m/z 86.1 Xle immonium ion. A key finding was that the relative intensity ratio (I44/I69) of these two diagnostic ions provided a robust basis for distinguishing between Leu and Ile. This novel approach was validated across diverse peptide samples. > The relative intensity ratio I44/I69 was newly identified as a robust basis for distinguishing Leu and Ile, successfully applied to linear and cyclic peptides of varying lengths. The strategy proved effective for characterizing both single and multiple Xle residues, demonstrating its broad applicability for accurate isomeric assignment.

Key Findings

  • Identified m/z 86.1 immonium ions from Xle residues via HCD.
  • Discovered two diagnostic product ions, m/z 44.0 and m/z 69.0, upon CID fragmentation of the immonium ion.
  • Established the relative intensity ratio (I44/I69) as a robust metric for distinguishing Leu vs. Ile.
  • Successfully applied the strategy to characterize single and multiple Xle residues in diverse peptides (linear/cyclic, short/long).

Why It Matters

This advanced mass spectrometry strategy significantly enhances the precision of peptide characterization, a critical step in peptide drug development and quality control. By enabling the direct and reliable assignment of Leu/Ile isomers, it addresses a long-standing analytical bottleneck. This method can be readily applied for rapid de novo sequencing of peptides, accelerating drug discovery. Furthermore, it allows for the accurate identification of Leu/Ile isomeric impurities, ensuring the structural integrity, safety, and consistent efficacy of peptide therapeutics. This could lead to more robust manufacturing processes and improved patient outcomes by guaranteeing the exact amino acid sequence of therapeutic peptides.


mass-spectrometry peptide-analysis leucine isoleucine analytical-method drug-development
Source: pubmed:42423382 · Ingested 2026-07-09 · Digest: gemini-2.5-flash